ReviewVeterinary research communications2026
Curcumin-based nanotherapeutics for colibacillosis in chickens: advances in veterinary microbiology.
Review in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most important bacterial agents of colibacillosis is Avian Pathogenic Escherichia coli (APEC), which affects the poultry industry by increasing mortality, reducing growth performance, and ultimately decreasing production efficiency. According the surveillance studies carried out in the European Union during the period of 2019-21, resistance to antibiotics has increased in E. coli due to transfer of genes between bacteria and humans. The rapid emergence of high antimicrobial resistance has accelerated research towards effective, natural, and antibiotic-free substitutes. Curcumin is a bioactive polyphenol extracted from Curcuma longa, has been widely studied for its antioxidant, immunomodulatory, antimicrobial, and anti-inflammatory properties. But, its use as a feed additive for chickens is limited because of the low bioavailability, rapid metabolism, and poor solubility. By applying nanotechnology techniques, researchers have successfully developed formulations that counteract these disadvantages and improve their bioavailability and stability. Curcumin nanoparticles work by causing damage to bacterial cell membrane, production of reactive oxygen species, and impeding bacterial cytokinesis by preventing the assembly of the FtsZ protein. Applications of nanoformulations of curcumin as a therapeutic agent for increasing the production of chicken, the various methods of delivering them to the birds, their pharmacokinetic studies and their effect on the growth performance of poultry birds have been critically and thoroughly analyzed in this review. Nanocurcumin at a concentration of 100 mg per kilogram of feed has demonstrated the best results for body weight gain, feed conversion ratio and feed intake. Despite the positive results, there are unsolved queries about the toxicokinetics, signaling molecular pathways, long-term safety, and dose standardization. For nanocurcumin to be logically incorporated into chicken health management, these obstacles must be overcome.
Indexed as
Identifiers
42867747What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.